83 results
Page 4 of 5
10-K
EX-10.20
o3gqpsyye6hd4ld3
1 Mar 21
Annual report
12:00am
10-K
ydttn
1 Mar 21
Annual report
12:00am
10-K
EX-10.33
t9kx gvlvfh
1 Mar 21
Annual report
12:00am
8-K
EX-99.1
z9aty9r3eitas o4i
11 Jan 21
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning
6:52am
8-K
EX-99.1
hywsb8imn5t3ky qa
6 Jan 21
Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China
4:08pm
6-K
EX-99.1
trvlsin9fuw 13x
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
6-K
EX-99.1
20mwmpfq
28 Dec 20
Zai Lab and Cullinan Oncology Announce Strategic
7:30am
6-K
2uj kqcz27swl9kf
9 Oct 20
Current report (foreign)
9:06am
6-K
EX-99.1
2yj1 2lhdbdf
28 Sep 20
Zai Lab Announces Closing of Hong Kong Secondary Listing
7:52am
424B5
cn1 zlda6o
23 Sep 20
Prospectus supplement for primary offering
8:06am
6-K
EX-99.1
mpp5hl6 5sbnpm
22 Sep 20
Zai Lab Announces Pricing of Hong Kong Secondary Listing
8:08am
6-K
EX-1.1
57eojuy1300d
21 Sep 20
Current report (foreign)
4:15pm
424B5
6frjt4tx6
16 Sep 20
Prospectus supplement for primary offering
7:24am
6-K
EX-99.1
acugv x14e
16 Sep 20
Zai Lab Launches Hong Kong Secondary Listing
7:18am
6-K
EX-99.1
u1x5stet l3uxms3y4
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
tmycih ig2og3ytcr
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
EX-99.1
1glauy
17 Aug 20
Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer
7:35am
6-K
EX-99.1
eopujc3fioo
13 Aug 20
Current report (foreign)
7:30am
6-K
EX-99.1
0iap9wg3nwu t1
20 Jul 20
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
7:35am
6-K
EX-99.1
8xflodavcgz0f99x3
7 Jul 20
Turning Point Therapeutics and Zai Lab Announce
7:35am